

Cover Story
The FDA Oncologic Drugs Advisory Committee Feb. 26 voted down a vascular-targeted photodynamic therapy for early-stage, low-risk prostate cancer and, in a narrow vote, recommended approval for a combination of a VEGF receptor 2 antagonist and an EGFR-targeting tyrosine kinase inhibitor for front-line treatment of EGFR-positive non-small cell lung cancer.
By Alexandria Carolan
In Brief
Clinical Roundup
Drugs & Targets


Trending Stories
- Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- ACOG says it will no longer accept federal funding
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”
- Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills